DNA technology for the detection of common genetic variants that predispose to thrombophilia

被引:14
作者
Pecheniuk, NM [1 ]
Walsh, TP [1 ]
Marsh, NA [1 ]
机构
[1] Queensland Univ Technol, Sch Life Sci, Cooperat Res Ctr Diagnost Technol, Brisbane, Qld 4001, Australia
关键词
thrombophilia; DNA technology; factor V Leiden; prothrombin; 20210; methylene tetrahydrofolate reductase; polymerase chain reaction; restriction fragment length polymorphism; minisequencing;
D O I
10.1097/00001721-200012000-00001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
With the identification of common single locus point mutations as risk factors for thrombophilia, many DNA testing methodologies have been described for detecting these variations. Traditionally, functional or immunological testing methods have been used to investigate quantitative anticoagulant deficiencies. However, with the emergence of the genetic variations, factor V Leiden, prothrombin 20210 and, to a lesser extent, the methylene tetrahydrofolate reductase (MTHFR677) and factor V HR2 haplotype, traditional testing methodologies have proved to be less useful and instead DNA technology is more commonly employed in diagnostics. This review considers many of the DNA techniques that have proved to be useful in the detection of common genetic variants that predispose to thrombophilia. Techniques involving gel analysis are used to detect the presence or absence of restriction sites, electrophoretic mobility shifts, as in single strand conformation polymorphism or denaturing gradient gel electrophoresis, and product formation in allele-specific amplification. Such techniques may be sensitive, but are unwielding and often need to be validated objectively. In order to overcome some of the limitations of gel analysis, especially when dealing with larger sample numbers, many alternative detection formats, such as closed tube systems, microplates and microarrays (minisequencing, real-time polymerase chain reaction, and oligonucleotide ligation assays) have been developed. In addition, many of the emerging technologies take advantage of colourimetric or fluorescence detection (including energy transfer) that allows qualitative and quantitative interpretation of results. With the large variety of DNA technologies available, the choice of methodology will depend on several factors including cost and the need for speed, simplicity and robustness. Blood Coagul Fibrinolysis 11:683-700 (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:683 / 700
页数:18
相关论文
共 170 条
[51]   A RAPID SCREENING METHOD FOR THE FACTOR-V ARG506-]GLN MUTATION [J].
GANDRILLE, S ;
ALHENCGELAS, M ;
AIACH, M .
BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (03) :245-248
[52]  
Giesendorf BAJ, 1998, CLIN CHEM, V44, P482
[53]   Factor V antigen levels in APC resistance, in factor V deficiency and in combined APC resistance and factor V deficiency (pseudohomozygosis for APC resistance) [J].
Girolami, A ;
Simioni, P ;
Venturelli, U ;
Girolami, B ;
Zanon, E .
BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 (04) :245-248
[54]  
Goldhaber S, 1994, HAEMOSTASIS THROMBOS, P1327
[55]  
Gomez E, 1997, BLOOD COAGUL FIBRIN, V8, P497
[56]  
Gou D, 1996, LANCET, V347, P59
[57]   Factor V Leiden-dependent APC resistance: Improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma [J].
GouaultHeilmann, M ;
LeroyMatheron, C .
THROMBOSIS RESEARCH, 1996, 82 (03) :281-283
[58]   ALTERNATIVE PCR METHOD FOR DIAGNOSIS OF MUTATION CAUSING ACTIVATED PROTEIN-C RESISTANT GLN(506)-FACTOR-V [J].
GREENGARD, JS ;
XU, X ;
GANDRILLE, S ;
GRIFFIN, JH .
THROMBOSIS RESEARCH, 1995, 80 (05) :441-443
[59]  
GRIFFIN JH, 1993, BLOOD, V82, P1989
[60]   DEFICIENCY OF PROTEIN-C IN CONGENITAL THROMBOTIC DISEASE [J].
GRIFFIN, JH ;
EVATT, B ;
ZIMMERMAN, TS ;
KLEISS, AJ ;
WIDEMAN, C .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1370-1373